Literature DB >> 12615726

Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells.

Christoph Benckert1, Sven Jonas, Thorsten Cramer, Zofia Von Marschall, Georgia Schäfer, Michael Peters, Karola Wagner, Cornelia Radke, Bertram Wiedenmann, Peter Neuhaus, Michael Höcker, Stefan Rosewicz.   

Abstract

The expression pattern and functional interaction of proangiogenic factors in human cholangiocellular carcinoma (CCC) have not been fully defined. We therefore investigated the expression of vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-beta 1 as well as their respective receptors in human CCC tumor samples and further analyzed their functional interaction in vitro. Expression of VEGF, TGF-beta 1, and their receptors was examined by immunohistochemistry, in situ hybridization, quantitative competitive reverse transcription-PCR, and ELISA. VEGF promoter analysis and identification of transcription factors involved in promoter regulation were investigated using transient transfection and electrophoretic mobility shift assays. We observed strong expression of VEGF in CCC tumor cells and localization of VEGF receptors 1 and 2 in endothelial cells; in addition, coexpression of TGF-beta 1 and its receptors in tumor cells suggests a possible functional interaction between both cytokines. In vitro studies confirmed a paracrine/autocrine stimulation of VEGF by TGF-beta 1 at a transcriptional level. Additional molecular studies using 5' deletion and mutational analysis of the human VEGF promoter revealed that TGF-beta 1 stimulates VEGF through Sp1-dependent transcriptional activation. These data suggest that overexpression and functional interaction of TGF-beta 1 and VEGF might contribute to the "angiogenic switch" and the malignant phenotype in human CCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615726

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

Review 1.  [Pathological anatomical characteristics of Klatskin tumors. Classification, current molecular biological aspects, prognosis factors].

Authors:  J Munding; A Tannapfel
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

2.  Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer.

Authors:  Christoph Benckert; Armin Thelen; Thorsten Cramer; Wilko Weichert; Gereon Gaebelein; Reinhard Gessner; Sven Jonas
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 3.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

4.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

5.  Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.

Authors:  Tetsuya Shimizu; Shigeki Yokomuro; Yoshiaki Mizuguchi; Yutaka Kawahigashi; Yasuo Arima; Nobuhiko Taniai; Yasuhiro Mamada; Hiroshi Yoshida; Koho Akimaru; Takashi Tajiri
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

6.  Clinical significance of serum levels of vascular endothelial growth factor and its receptor in biliary disease and carcinoma.

Authors:  Munechika Enjoji; Makoto Nakamuta; Koji Yamaguchi; Satoshi Ohta; Kazuhiro Kotoh; Marie Fukushima; Masami Kuniyoshi; Tomomi Yamada; Masao Tanaka; Hajime Nawata
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

7.  Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.

Authors:  Giammarco Fava; Sharon Demorrow; Eugenio Gaudio; Antonio Franchitto; Paolo Onori; Guido Carpino; Shannon Glaser; Heather Francis; Monique Coufal; Luca Marucci; Domenico Alvaro; Marco Marzioni; Trenton Horst; Romina Mancinelli; Antonio Benedetti; Gianfranco Alpini
Journal:  Liver Int       Date:  2009-03-09       Impact factor: 5.828

8.  Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells.

Authors:  Carl E Allen; Jianguo Du; Bo Jiang; Qin Huang; Adam J Yakovich; John A Barnard
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

9.  Overexpression and interactions of interleukin-10, transforming growth factor beta, and vascular endothelial growth factor in esophageal squamous cell carcinoma.

Authors:  Mehran Gholamin; Omeed Moaven; Bahram Memar; Moein Farshchian; Hossein Naseh; Reza Malekzadeh; Masoud Sotoudeh; Mohammad Taghi Rajabi-Mashhadi; Mohammad Naser Forghani; Farid Farrokhi; Mohammad Reza Abbaszadegan
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

10.  Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma.

Authors:  Zhu-Qing Zhou; Wei-Hua Cao; Jian-Jun Xie; Jing Lin; Zhong-Ying Shen; Qing-Ying Zhang; Jin-Hui Shen; Li-Yan Xu; En-Min Li
Journal:  BMC Cancer       Date:  2009-08-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.